Back to Journals » Neuropsychiatric Disease and Treatment » Volume 6 » Issue 1

Current trends in drug treatment of obsessive–compulsive disorder

Authors Decloedt E, Stein D

Published 10 May 2010 Volume 2010:6(1) Pages 233—242

DOI https://doi.org/10.2147/NDT.S3149

Review by Single-blind

Peer reviewer comments 2


Eric H Decloedt1, Dan J Stein2

1Department of Internal Medicine, Division of Clinical Pharmacology, 2Department of Psychiatry, University of Cape Town, South Africa

Abstract: This article aims to highlight current trends in the pharmacologic management of obsessive–compulsive disorder (OCD). A systematic search of the electronic database MEDLINE was conducted. The first case report of clomipramine efficacy in the management OCD more than 40 years ago gave new hope for the treatment of this debilitating disorder. Selective serotonin reuptake inhibitors (SSRIs) proved to have a similar efficacy profile compared with clomipramine but had a superior tolerability profile. While many patients with OCD respond to SSRIs or clomipramine, the treatment of those with refractory OCD remains challenging. Different augmentation agents in treatment-resistant OCD have been explored, with antipsychotic agents having the largest supporting evidence base. Nevertheless, new pharmacologic treatment options are required and are under investigation.
Keywords: obsessive–compulsive disorder, pharmacology, treatment, drug

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]